GCA
IMMU

Gideon Capital Advisors’s Immunomedics Inc IMMU Stock Holding History

Gideon Capital Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,970
Closed -$229K – 545
2018
Q3 		$229K Buy
+10,970
New +$260K 0.11% 298

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Gideon Capital Advisors's IMMU Position: Q4 2018 in Review

Gideon Capital Advisors sold out of Immunomedics Inc (IMMU) in Q4 2018, closing a stake of 10,970 shares — an estimated $229K sold.

Gideon Capital Advisors first reported a position in IMMU in Q3 2018 and held it in 1 quarter. The position peaked at $229K in Q3 2018. 205 funds tracked by Wall St. Rank hold IMMU as of Q4 2018.

  • Gideon Capital Advisors reported no remaining Immunomedics Inc position as of Q4 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 10,970 Immunomedics Inc shares in Q4 2018, an estimated $229K.
  • Gideon Capital Advisors first reported a position in Immunomedics Inc in Q3 2018 and held it in 1 quarter.
  • Gideon Capital Advisors's Immunomedics Inc position peaked at $229K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.